Skip to main content

Medical Oncology Clinic

The Institut Bordet Medical Oncology Clinic has a number of roles:

  • diagnosis and therapeutic care of patients with solid tumours
  • overseeing administration of cancer medication for in-patients and out-patients
  • monitoring patients during and after their treatment.

The Clinic takes a multidisciplinary approach. Therapeutic decisions are made in consultation with other specialist doctors and healthcare professionals involved in the patient’s care.
The aim is that patients should be monitored in all respects, including psychologically.

The Medical Oncology Clinic forms an integral part of the Department of Medicine. It is also very active in clinical research (particularly in the development of new medication) and translational research. At the Clinic, research is integrated into the care provided, enabling patients to benefit from the latest diagnostic and therapeutic advances, well before these become part of clinical routine.

Research projects

Project 1

AURORA Programme aimed at understanding the molecular characteristics of recurrent and metastatic breast cancer early in the evolution of metastatic disease.

Project 2

CORIOLAN Study to analyse the performance of new imaging techniques for monitoring and determining the prognosis of patients with advanced stage colorectal cancer

Project 3

CAR-T Project (Think Clinical Trial)

Project 4

NeoRHEA Clinical Study
  • Project holder : Michael Ignatiadis
  • Collaboration(s) : Belgian Hospitals and Oncology Centres
  • Funding (or) Support : Pfizer

Project 5

MIME Clinical Study

Project 6

TP53 targeting in BRAF mutation melanoma

Our team

Head of the Medical Oncology Clinic
Pr A. Awada

Solid and Rare Tumours
New Innovative Treatments
Pr A. Awada
Dr Ph. Aftimos
Dr S. Aspeslagh
Dr Ch. Jungels
Dr N. Kotecki

Breast Oncology
Pr M. Piccart
Dr D. de Valeriola
Pr Ch. Sotiriou
Dr E. de Azambuja
Dr A. Gombos
Dr M. Ignatiadis
Dr F. Lebrun
Dr L. Polastro
Dr Ph. Aftimos
Dr D. t’Kint de Roodenbeke
Dr L. Buisseret

Dr L. Dal Lago

Cervico-facial Oncology  
Dr Y. Lalami

Skin Tumour Oncology                
Dr J. Kerger / Pr A. Awada
Dr M. Suppa

Digestive Oncology     
Dr A. Hendlisz
Dr A. Deleporte
Dr G. Machiels
Dr F. Puleo
Dr L. Shaza
Dr L. Polastro (with the exception of gastroenterology/endoscopy)

Gynaecological Oncology
Dr J. Kerger
Dr F. Lebrun
Dr L. Polastro
Dr D. t’Kint de Roodenbeke

Thoracic Oncology
Pr J.-P. Sculier
Pr Th. Berghmans
Pr A.-P. Meert
Dr B. Grigoriu

Urogenital Oncology
Bone and Soft Tissue Tumour Oncology
Dr Th. Gil
Dr S. Sideris
Dr N. Martínez-Chanza (urogénital)
Dr Ch. Jungels (sarcomes)

Pr M. Abramowicz
Dr D. t’Kint de Roodenbeke
Dr I. Vandernoot

Central Nervous System Oncology
Pr E. de Azambuja

Consultants :    
Pr J. Klastersky (médecine interne/oncologie)

Dr A. Covas (gastroentérologie/oncologie digestive)
Dr Z. El Ali (oncologie médicale)
Dr S. Latifyan (oncologie médicale)
Dr D. Levacq (oncologie médicale)

 Scientific publications

Choice of chemotherapy regimen for early HER2-positive breast cancer in elderly patients.

Authors : Pondé N, de Azambuja E
Year : 2018
Journal : Chin Clin Oncol
Volume : 7(1)
Pages : 4

Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis.

Authors : Debiasi M, Polanczyk CA, Ziegelmann P, Barrios C, Cao H, Dignam JJ, Goss P, Bychkovsky B, Finkelstein DM, Guindalini RS, Filho P, Albuquerque C, Reinert T, de Azambuja E, Olopade O
Year : 2018
Journal : Front Oncol
Volume : 8
Pages : 156

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

Authors : Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber Rd, Campbell I, Nordenskjöld B, Gutiérez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph DJ, Crown J, Piccart-Gebhart M, Francis PA
Year : 2018
Journal : Int J Radiat Oncol Biol Phys
Volume : 101(2)
Pages : 316-324.

Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.

Authors : Ignatiadis M, Litière S, Rothe F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart M, Sotiriou C, Rack B, Pierga JY
Year : 2018
Journal : Ann Oncol

Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: a TransHERA study.

Authors : Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont DP, Rojo F, Viale G, Toi M, Harbeck N, Pritchard KI, Gelber Rd, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart M, Dowsett M
Year : 2018
Journal : Clin Cancer Res
Volume : 24(13)
Pages : 3079-3086

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more